Search results
Clovis (CLVS) Stock Down 50% in the Past 6 Months: Here's Why
Zacks via Yahoo Finance· 2 years agoClovis Oncology, Inc.’s CLVS shares have plunged 49.6% in the past six months against the industry’s...
Down 67.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Clovis (CLVS)
Zacks via Yahoo Finance· 2 years agoClovis (CLVS) has become technically an oversold stock now, which implies exhaustion of the heavy...
Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know
Zacks via Yahoo Finance· 2 years agoClovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings...
Clovis Oncology (CLVS) Reports Q3 Loss, Lags Revenue Estimates
Zacks via Yahoo Finance· 2 years agoClovis (CLVS) delivered earnings and revenue surprises of 7.14% and 11.87%, respectively, for the...
Zacks.com featured highlights include Clovis Oncology, NiSource, DocuSign, Root and Endava
Zacks via Yahoo Finance· 1 year agoFor Immediate Release Chicago, IL – December 22, 2022 – Stocks in this week’s article are Clovis...
Clovis (CLVS) Q2 Loss Wider Than Expected, Revenues Miss
Zacks via Yahoo Finance· 2 years agoClovis (CLVS) incurs a wider-than-estimated loss in second-quarter 2022. Sales of the sole marketed...
Clovis (CLVS) Seeks Nod for Rubraca in First Line Ovarian Cancer
Zacks via Yahoo Finance· 2 years agoClovis (CLVS) files regulatory applications in the United States and Europe seeking label expansion...
7 Penny Stocks to Buy Before the Bull Market Returns
InvestorPlace via Yahoo Finance· 2 years agoIn recent weeks, the stock market has stabilized after June’s sell-off, but it may take time before bullishness makes a comeback. Plenty of uncertainty...
Why Clovis Oncology Zoomed 30% Higher Today
Motley Fool· 2 years agoCancer-focused biotech Clovis Oncology (NASDAQ: CLVS) was a stock on fire Monday. On Sunday, Clovis reported that Rubraca tested very well as a...
Why Clovis Oncology Stock Trounced the Market Today
Motley Fool· 2 years agoClovis Oncology (NASDAQ: CLVS) had a fine Tuesday, with its share price rising by almost 5% to beat the performance of many other biotech stocks, not to mention the S&P 500 index. A new deal ...